Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

About Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:VNDA
  • CUSIP: 92165910
  • Web: www.vandapharmaceuticals.com
Capitalization:
  • Market Cap: $838.84 million
  • Outstanding Shares: 44,858,000
Average Prices:
  • 50 Day Moving Avg: $16.57
  • 200 Day Moving Avg: $15.25
  • 52 Week Range: $12.70 - $18.99
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -85.00
  • P/E Growth: -2.86
Sales & Book Value:
  • Annual Revenue: $156.2 million
  • Price / Sales: 5.37
  • Book Value: $2.93 per share
  • Price / Book: 6.38
Profitability:
  • EBIDTA: ($4,150,000.00)
  • Net Margins: -6.54%
  • Return on Equity: -7.85%
  • Return on Assets: -4.90%
Debt:
  • Current Ratio: 2.31%
  • Quick Ratio: 2.30%
Misc:
  • Average Volume: 536,589 shs.
  • Beta: 1.47
  • Short Ratio: 5.77
 

Frequently Asked Questions for Vanda Pharmaceuticals (NASDAQ:VNDA)

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Wednesday, August, 2nd. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.18. The company earned $42.06 million during the quarter, compared to analysts' expectations of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. Vanda Pharmaceuticals's quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.01 EPS. View Vanda Pharmaceuticals' Earnings History.

When will Vanda Pharmaceuticals make its next earnings announcement?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Vanda Pharmaceuticals.

Where is Vanda Pharmaceuticals' stock going? Where will Vanda Pharmaceuticals' stock price be in 2017?

7 brokers have issued 12 month price objectives for Vanda Pharmaceuticals' shares. Their forecasts range from $18.00 to $26.00. On average, they anticipate Vanda Pharmaceuticals' stock price to reach $22.14 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:

  • H. Thomas Watkins, Independent Chairman of the Board
  • Mihael Hristos Polymeropoulos M.D., President, Chief Executive Officer, Director
  • James Patrick Kelly, Chief Financial Officer, Senior Vice President, Treasurer, Secretary
  • Richard L Gulino, Senior Vice President, General Counsel, Secretary
  • Gian Piero Reverberi, Senior Vice President, Acting Chief Commercial Officer and European General Manager
  • Kenneth M. Bate, Director
  • Michael F. Cola, Independent Director
  • Richard W. Dugan, Independent Director
  • Vincent J. Milano, Independent Director

Who owns Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Palo Alto Investors LLC (9.37%), Vanguard Group Inc. (6.00%), Macquarie Group Ltd. (3.80%), State Street Corp (3.61%), FMR LLC (3.58%) and Renaissance Technologies LLC (2.46%). Company insiders that own Vanda Pharmaceuticals stock include James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos, Paolo Baroldi and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Who sold Vanda Pharmaceuticals stock? Who is selling Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, TIAA CREF Investment Management LLC, Candriam Luxembourg S.C.A., Nexthera Capital LP, Wells Fargo & Company MN, Prudential Financial Inc., Columbus Circle Investors and Pacad Investment Ltd.. View Insider Buying and Selling for Vanda Pharmaceuticals.

Who bought Vanda Pharmaceuticals stock? Who is buying Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, AJO LP, Vanguard Group Inc., Renaissance Technologies LLC, Macquarie Group Ltd., Spark Investment Management LLC, Ameriprise Financial Inc. and Numeric Investors LLC. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy Vanda Pharmaceuticals stock?

Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $18.70.


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  259 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.14 (18.41% upside)

Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$21.00HighView Rating Details
9/14/2017Piper Jaffray CompaniesBoost Price TargetOverweight -> Overweight$23.00 -> $26.00HighView Rating Details
8/29/2017Jefferies Group LLCReiterated RatingBuy$21.00HighView Rating Details
8/3/2017HC WainwrightSet Price TargetBuy$18.00HighView Rating Details
4/12/2017CIBCReiterated RatingOutperform -> Outperform$21.00LowView Rating Details
11/9/2016AegisInitiated CoverageBuy$24.00N/AView Rating Details
10/10/2016Brean CapitalSet Price TargetBuy$24.00N/AView Rating Details
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 -> $22.00N/AView Rating Details
3/14/2016Canaccord GenuityReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Earnings by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Earnings History by Quarter for Vanda Pharmaceuticals (NASDAQ VNDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.15)N/AView Earnings Details
8/2/2017Q2 2017($0.21)($0.03)$40.31 million$42.06 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.13)($0.17)$38.35 million$37.42 millionViewListenView Earnings Details
2/15/2017Q416($0.06)($0.01)$39.38 million$38.24 millionViewListenView Earnings Details
11/2/2016Q316($0.14)($0.01)$38.05 million$38.48 millionViewListenView Earnings Details
7/27/2016Q216($0.23)($0.11)$36.03 million$36.02 millionViewListenView Earnings Details
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details
2/10/2011($0.02)$0.08ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)
2017 EPS Consensus Estimate: ($0.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.18)($0.15)($0.17)
Q2 20172($0.27)($0.20)($0.24)
Q3 20172($0.13)($0.08)($0.11)
Q4 20172($0.18)($0.10)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 86.49%
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Richard L GulinoSVPSell10,900$15.51$169,059.00View SEC Filing  
9/23/2016James E FlynnInsiderSell1,120,461$16.56$18,554,834.16View SEC Filing  
9/19/2016James E FlynnInsiderSell547,886$15.66$8,579,894.76View SEC Filing  
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.44View SEC Filing  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88View SEC Filing  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.80View SEC Filing  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52View SEC Filing  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vanda Pharmaceuticals (NASDAQ:VNDA)
Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
Source:
DateHeadline
americanbankingnews.com logo$44.50 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - September 22 at 3:22 AM
finance.yahoo.com logoThese 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?
finance.yahoo.com - September 19 at 9:22 AM
seekingalpha.com logoVanda Pharmaceuticals (VNDA) Presents At Morgan Stanley 15th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - September 15 at 11:05 AM
finance.yahoo.com logoIs It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)?
finance.yahoo.com - September 15 at 11:05 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Earns "Buy" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 14 at 3:32 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Price Target Increased to $26.00 by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - September 14 at 9:08 AM
marketwatch.com logoVanda Pharma shares decline as goal of itch drug study not reached - MarketWatch
www.marketwatch.com - September 13 at 9:00 PM
finance.yahoo.com logoVanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis
finance.yahoo.com - September 13 at 9:00 PM
finance.yahoo.com logoVanda Pharma shares decline as goal of itch drug study not reached
finance.yahoo.com - September 13 at 9:00 PM
seekingalpha.com logoVanda Pharmaceuticals (VNDA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 3:57 PM
finance.yahoo.com logoVanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences
finance.yahoo.com - September 12 at 11:52 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 9 at 1:30 PM
finance.yahoo.com logoVanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference
finance.yahoo.com - September 7 at 10:56 AM
americanbankingnews.com logoJefferies Group Equities Analysts Reduce Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - August 31 at 8:48 AM
americanbankingnews.com logoJefferies Group Brokers Increase Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - August 30 at 1:48 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - August 29 at 1:04 PM
finance.yahoo.com logoLooking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice
finance.yahoo.com - August 29 at 9:29 AM
finance.yahoo.com logo5 Efficient Stocks to Buy for a Healthy Portfolio
finance.yahoo.com - August 25 at 12:24 PM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : August 21, 2017
finance.yahoo.com - August 23 at 1:39 PM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : August 23, 2017
finance.yahoo.com - August 23 at 1:39 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Upgraded at BidaskClub
www.americanbankingnews.com - August 22 at 12:44 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Expected to Announce Quarterly Sales of $44.50 Million
www.americanbankingnews.com - August 16 at 4:04 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 12:16 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Downgraded by BidaskClub
www.americanbankingnews.com - August 11 at 7:50 PM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : August 9, 2017
finance.yahoo.com - August 10 at 9:29 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. Expected to Earn Q3 2017 Earnings of ($0.13) Per Share (NASDAQ:VNDA)
www.americanbankingnews.com - August 7 at 7:12 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Vanda Pharmaceuticals Inc. Boosted by Analyst (VNDA)
www.americanbankingnews.com - August 7 at 7:12 AM
bizjournals.com logoD.C. biotech is angling for massive market to treat jet lag disorders
www.bizjournals.com - August 5 at 8:16 AM
bizjournals.com logoVanda Pharmaceuticals preps for jet lag study results later this year - Washington Business Journal
www.bizjournals.com - August 5 at 8:16 AM
finance.yahoo.com logoVanda Pharmaceuticals preps for jet lag study results later this year
finance.yahoo.com - August 5 at 8:16 AM
americanbankingnews.com logoFY2021 EPS Estimates for Vanda Pharmaceuticals Inc. Lifted by Analyst (NASDAQ:VNDA)
www.americanbankingnews.com - August 4 at 8:00 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS
www.americanbankingnews.com - August 3 at 3:58 PM
seekingalpha.com logoVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 3 at 8:40 AM
finance.yahoo.com logoVanda Pharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 8:40 AM
finance.yahoo.com logoVanda reports 2Q loss
finance.yahoo.com - August 3 at 8:40 AM
finance.yahoo.com logoEdited Transcript of VNDA earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 8:40 AM
americanbankingnews.com logoCritical Comparison: Vanda Pharmaceuticals (VNDA) & bluebird bio (BLUE)
www.americanbankingnews.com - July 28 at 2:30 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce -$0.21 EPS
www.americanbankingnews.com - July 27 at 11:17 AM
seekingalpha.com logoVanda Pharmaceuticals: An Early Stage Bioscience Consideration - Seeking Alpha
seekingalpha.com - July 27 at 9:15 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:58 AM
finance.yahoo.com logoVanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia
finance.yahoo.com - July 22 at 10:21 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 10:56 AM
streetinsider.com logoVanda Pharmaceuticals (VNDA) Announces Negative Opinion from EMA on Fanaptum for Treatment of Schizophrenia - StreetInsider.com
www.streetinsider.com - July 21 at 8:28 AM
prnewswire.com logoVanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017 - PR Newswire (press release)
www.prnewswire.com - July 19 at 4:09 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - July 18 at 12:14 PM
finance.yahoo.com logoVanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017
finance.yahoo.com - July 17 at 10:47 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Lowered by Analyst
www.americanbankingnews.com - July 17 at 7:06 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
finance.yahoo.com - July 14 at 4:59 PM
americanbankingnews.com logo$40.37 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - July 5 at 11:47 AM
americanbankingnews.com logoZacks: Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) to Announce -$0.23 EPS
www.americanbankingnews.com - July 3 at 10:14 AM

Social

Chart

Vanda Pharmaceuticals (VNDA) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff